In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

Market OverviewThe Global Breast Cancer Therapeutics Market  remains one of the most prevalent forms of cancer worldwide, ...

Deemed as the “drug that changed the breast cancer treatment landscape,” Herceptin has saved millions of women's lives ...

Their original ADC, called Enhertu (trastuzumab deruxtecan), secured its seventh ... An earlier antibody-drug conjugate ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult pat ...

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

Indicates growing incidence of cancer among Indian population; five out of top 20 new brand launches are cancer drugs ...